Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials

Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials

Objectives: Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for black individuals vs non-black individuals. HCV trials submitted to the Food and Drug Administration (2013–2017) to support appr...

Full description

Bibliographic Details
Main Authors:	Kimberly Struble, Kirk Chan-Tack, Karen Qi, Thamban Valappil, Sarah Connelly, Poonam Mishra, Dionne Price, Jeffrey Murray, Debra Birnkrant
Format:	Article
Language:	English
Published:	Elsevier 2019-07-01
Series:	Journal of Virus Eradication
Subjects:	hepatitis C clinical trial Food and Drug Administration
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664020300431

Similar Items

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
by: Pellicelli Adriano M, et al.
Published: (2012-11-01)

The clinical and virological characteristics of HCV genotype 6 in Southern Taiwan
by: Yen-ChengChiu, et al.
Published: (2017)

VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3
by: Muhammad Sarfraz, et al.
Published: (2020-03-01)

Urinary metabolomics of HCV patients with severe liver fibrosis before and during the sustained virologic response achieved by direct acting antiviral treatment
by: Elisa Biliotti, et al.
Published: (2021-11-01)

Sustained virological response according to the type of early virological response in HCV and HCV/HIV
by: Paulo R. Lerias de Almeida, et al.
Published: (2010-04-01)

Liver Remodeling on CT Examination in Patients with HCV Compensated Cirrhosis Who Achieved Sustained Virological Response after Direct-Acting Antivirals Treatment
by: Florin Mihai, et al.
Published: (2020-04-01)

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
by: Paolucci S, et al.
Published: (2019-07-01)

Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy
by: Luca Arcaini, et al.
Published: (2012-01-01)

Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents
by: Minosse C, et al.
Published: (2018-11-01)

Acute Hepatitis HCV genotype 3h: virological baseline characterization and monitoring “On Therapy”
by: Giuseppe Sodano, et al.
Published: (2010-12-01)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
by: Andrea Angeletti, et al.
Published: (2019-02-01)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
by: Óscar Brochado-Kith, et al.
Published: (2021-08-01)

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
by: Nancy Abdel Fattah Ahmed, et al.
Published: (2020-08-01)

Virologic Tools for HCV Drug Resistance Testing
by: Slim Fourati, et al.
Published: (2015-12-01)

Virological Mechanisms in the Coinfection between HIV and HCV
by: Maria Carla Liberto, et al.
Published: (2015-01-01)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017-10-01)

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
by: Cody Orr, et al.
Published: (2020-12-01)

Virological impact of HCV elimination with DAAs in the HIV reservoir in HIV/HCV patients
by: M. Coiras, et al.
Published: (2019-12-01)

Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control
by: Mohamed Mohei El Badry, et al.
Published: (2020-11-01)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
by: Fabrizio Fabrizi, et al.
Published: (2019-10-01)

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank.
by: Dimas Alexandre Kliemann, et al.
Published: (2016-01-01)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
by: Calogero Armando, et al.
Published: (2019-01-01)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
by: Sonia Vibhakar Patel, et al.
Published: (2020-01-01)

Improvement in Waldenström’s Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals
by: Mattia Crespi, et al.
Published: (2018-11-01)

Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy
by: M.G. Deneke, et al.
Published: (2014-01-01)

Sustained virological response after treatment with direct‐acting antivirals can help immune reconstitution in HIV‐HCV coinfected patients even in case of persistent HIV low‐level viremia
by: Monica Basso, et al.
Published: (2021-03-01)

Modeling HCV Disease in Animals: Virology, Immunology and Pathogenesis of HCV and GBV-B Infections
by: Cordelia eManickam, et al.
Published: (2014-12-01)

HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection
by: Monica Basso, et al.
Published: (2021-04-01)

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
by: Nadia Marascio, et al.
Published: (2019-05-01)

Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct‐Acting Antivirals for Hepatitis C
by: Jason J. Pan, et al.
Published: (2018-11-01)

INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES
by: Vanessa Gutierrez de ANDRADE, et al.

Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes
by: Juliana Piedade, et al.
Published: (2021-06-01)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
by: Armando Calogero, et al.
Published: (2019-01-01)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
by: Victor Virlogeux, et al.
Published: (2017-12-01)

Changes in tryptophan and phenylalanine in chronic HCV patients treated with direct acting antiviral (sofosbuvir)
by: Eman G. Behiry, et al.
Published: (2018-11-01)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
by: Claudia Minosse, et al.
Published: (2021-06-01)

EVALUATION OF EFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C, CAUSED BY HCV GENOTYPE 6
by: D. A. Lioznov, et al.
Published: (2017-04-01)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals <sup>†</sup>
by: Silvia Molina-Carrión, et al.
Published: (2020-07-01)

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
by: Giuseppe Bruno, et al.
Published: (2017-09-01)

Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
by: Inas E L-Khedr Mohamed, et al.
Published: (2021-04-01)